Millennium Capital Advisors LLC Purchases New Position in SPDR S&P Biotech ETF $XBI

Millennium Capital Advisors LLC purchased a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 4,724 shares of the exchange traded fund’s stock, valued at approximately $576,000.

Several other institutional investors have also bought and sold shares of the stock. JPMorgan Chase & Co. boosted its stake in SPDR S&P Biotech ETF by 27.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 13,538,738 shares of the exchange traded fund’s stock valued at $1,356,582,000 after buying an additional 2,900,633 shares in the last quarter. Bessemer Group Inc. boosted its stake in SPDR S&P Biotech ETF by 13.5% in the 4th quarter. Bessemer Group Inc. now owns 1,853,232 shares of the exchange traded fund’s stock valued at $225,965,000 after buying an additional 220,244 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in SPDR S&P Biotech ETF by 40.5% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,226,147 shares of the exchange traded fund’s stock valued at $122,906,000 after buying an additional 353,351 shares in the last quarter. Meitav Investment House Ltd. boosted its stake in SPDR S&P Biotech ETF by 70.3% in the 3rd quarter. Meitav Investment House Ltd. now owns 682,056 shares of the exchange traded fund’s stock valued at $68,156,000 after buying an additional 281,602 shares in the last quarter. Finally, Greenhouse Funds LLLP boosted its stake in SPDR S&P Biotech ETF by 16.6% in the 3rd quarter. Greenhouse Funds LLLP now owns 675,975 shares of the exchange traded fund’s stock valued at $67,733,000 after buying an additional 96,308 shares in the last quarter.

SPDR S&P Biotech ETF Stock Performance

Shares of XBI opened at $130.69 on Friday. The stock has a fifty day moving average price of $129.38 and a two-hundred day moving average price of $124.41. SPDR S&P Biotech ETF has a 52-week low of $77.33 and a 52-week high of $139.19. The company has a market cap of $8.34 billion, a price-to-earnings ratio of 11.47 and a beta of 0.85.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.